Autoimmunity Reviews

Papers
(The H4-Index of Autoimmunity Reviews is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Editorial Board189
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis150
Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases139
The BAFF/APRIL system at the crossroads of B cell memory and autoimmune relapse: Implication into the therapeutic strategies126
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence116
The Trm-Treg Axis as a tissue-encoded immune checkpoint in chronic inflammation and autoimmunity111
Issues in autoantibody tests used in the classification criteria for autoimmune rheumatic diseases: the laboratory autoimmunologist's perspective105
Endometriosis and autoimmunity100
T lymphocyte plasticity in chronic inflammatory diseases: The emerging role of the Ikaros family as a key Th17-Treg switch99
Editorial Board98
MTHFR polymorphisms in autoimmune diseases: Mechanistic and clinical perspectives96
Susac syndrome: A scoping review94
The role of musculoskeletal ultrasound in difficult-to-treat RA: Insights from a systematic literature review93
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders85
Epidemiological patterns and in-hospital mortality in ANCA-associated vasculitis: Insights from Spain's National Health Data (2016–2022)83
Autoantibody internalization in myositis skeletal muscle: Emerging evidence, mechanistic insights, and therapeutic relevance80
Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: A systematic review and meta-analysis79
Comment on “Meta-analysis of meteorological conditions and rheumatoid arthritis”78
Worsening of Graves' ophthalmopathy after SARS-CoV-2 mRNA vaccination74
Idiopathic pericarditis in 2025: Advances in diagnosis and therapeutic strategies71
Fecal microbiota transplantation in autoimmune diseases – An extensive paper on a pathogenetic therapy66
To treat or not to treat rheumatoid arthritis with glucocorticoids? A reheated debate63
Metabolic traits of T cells and the implications in autoimmune diseases62
Editorial Board61
A call for uniformity in reporting patient level details during description of ophthalmologic major relapse among giant cell arteritis studies. A comment on article by Aussedat M et al. “Epidemiology 61
Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis reconsidered61
Homocysteine as a trigger and potential therapeutic target for autoimmune diseases56
Corrigendum to “Proportion of circulating T follicular helper cells in peripheral blood of systemic lupus erythematosus patients: A systematic review and meta-analysis” [Autoimmunity Reviews Volume 2455
Rebalancing redox homeostasis: A pivotal regulator of the cGAS-STING pathway in autoimmune diseases54
Understanding the effects of Janus kinase inhibitors on the cardiovascular system in comparison to main biological DMARDs in rheumatoid arthritis54
STING-inflammasome axis in autoimmune diseases and inflammation-related disease52
Autoimmune pre-disease52
Human abdominal aortic aneurysm (AAA): Evidence for an autoimmune antigen-driven disease.51
Psychiatric manifestations of autoimmune encephalitis51
Autoimmunity, diet and autophagy51
Conceiving complexity: Biological mechanisms underpinning the lasting effect of pregnancy on multiple sclerosis outcomes51
Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy50
WITHDRAWN: Global incidence trends of autoimmune diseases from 1990 to 2021 and projections to 2050: A systemic analysis of the global burden of disease study 202147
Can anticoagulation be withdrawn in APS patients after aPL negativization?47
Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature46
The immune system in Hashimoto's thyroiditis: Updating the current state of knowledge on potential therapies and animal model construction46
Advances in precision medicine in imaging and therapeutic strategies for psoriatic disease46
Seronegative autoimmune diseases: A challenging diagnosis45
Specialized pro-resolving mediators and autoimmunity: Recent insights and future perspectives44
Editorial Board44
0.99386096000671